ALKERMES PLC (ALKS)
IE00B56GVS15 - Common Stock
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of...
First Week of June 21st Options Trading For Alkermes (ALKS)
Alkermes to Report First Quarter Financial Results on May 1, 2024
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, May 1, 2024 to...
Investors should take notice of NASDAQ:ALKS—it offers a great deal for the fundamentals it presents.
Don't overlook ALKERMES PLC (NASDAQ:ALKS)—it's a hidden gem with strong fundamentals and an attractive price tag.
Oversold Conditions For Alkermes (ALKS)
Exploring growth characteristics of ALKERMES PLC (NASDAQ:ALKS).
ALKERMES PLC (NASDAQ:ALKS) may be suited for growth investing, we'll explore why in this article.
Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the oral presentation of clinical data at the 2024 Congress of the Schizophrenia International...
Noteworthy Tuesday Option Activity: ALKS, DKNG, VRT
First Week of ALKS November 15th Options Trading
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors...
Amicus Therapeutics Stock Sees RS Rating Improve To 74
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday.
Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat
Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81.
Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark
Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84.
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024
Biotech stocks are often at the forefront of innovation. These picks are worth considering for your portfolio for their growth potential.
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks are often at the forefront of innovation. These are the companie...
Alkermes downgraded at UBS as stock nears 52-week high (NASDAQ:ALKS)
UBS downgrades Alkermes to sell due to disappointing sales and negative pipeline update. Read more here.
Notable Friday Option Activity: CMP, ALKS, JPM
Alkermes Stock Gets RS Rating Upgrade; Profits Surge
In a welcome move, biotech Alkermes stock saw its Relative Strength Rating improve from 69 to 75 on Thursday.
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2023 and provided financial expectations...
CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+
CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Alkermes (ALKS) Shares Cross Above 200 DMA
7 Biotech Stocks Fighting America’s Deadliest Diseases
Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship.
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Thursday, Feb. 15, 2024 to...
Madrigal Pharmaceuticals Stock Shows Rising Relative Strength
A Relative Strength Rating upgrade for Madrigal Pharmaceuticals shows improving technical performance.
The 3 Best Biotech Stocks to Invest in for Big Gains in 2024
These pivotal biotech stocks for gains are charting the future of medicine and investment growth in 2024 offering powerful returns
3 Top Pharma Stocks to Buy Now: February 2024
Discover why these three pharma stocks should be on your buy list in February 2024 - they could be your ticket to explosive portfolio growth.
3 Top Pharma Stocks to Buy Now: February 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Looking for pharma stocks to buy in February 2024? The pharmaceutical indust...